Friday, November 13, 2026

ServiceNow Buys Pyramid Analytics as Global Enterprise SaaS Race for AI Turns to Acquisitions

ServiceNow has acquired Pyramid Analytics, an AI-powered business intelligence platform backed by Israeli VC firm JVP and Insight Ventures. The deal accelerates a global consolidation wave: incumbents like SAP, Oracle, and Salesforce face narrowing windows to close AI capability gaps against cloud-native rivals. Two to four similar cross-border deals are projected within 90 days.

LM Salvado
LM Salvado

May 31, 2026

This article was written by AI. Published before our source requirement (10 August 2026); sources were not recorded. How we work

ServiceNow Buys Pyramid Analytics as Global Enterprise SaaS Race for AI Turns to Acquisitions
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

ServiceNow has acquired Pyramid Analytics, an AI-powered business intelligence platform backed by Israeli venture firm JVP and Insight Ventures, in a move that signals a global shift in how enterprise software incumbents are competing for AI dominance.1

The deal gives ServiceNow embedded AI analytics without the years of in-house development organic growth would require. Pyramid had already validated its model with enterprise customers across multiple markets — a track record acquirers absorb instantly.1

The pattern spans continents. SAP in Germany, Oracle and Salesforce in the United States, and their global-tier peers all face the same pressure: close AI capability gaps against cloud-native competitors before the window closes.1 Inorganic growth compresses that timeline far faster than building from scratch.

JVP, operating from Israel with a deep enterprise software portfolio, and Insight Ventures had positioned Pyramid for exactly this kind of strategic exit. Venture-backed AI analytics firms at the growth stage have become the preferred acquisition target globally — already validated, already trusted by customers.

Two to four similar acquisitions are projected within the next 90 days as rivals respond.1 Competitive logic cascades: once one incumbent moves, peers face pressure to match or fall further behind.

For enterprise buyers from Frankfurt to Singapore to São Paulo, the implications are direct. AI analytics capabilities once purchased as standalone tools will increasingly arrive bundled inside platforms organizations already run. Point-solution vendors face both elevated acquisition interest and commoditization pressure from the platforms consolidating above them.

The build-versus-buy debate in enterprise AI is over. Acquisition is the global playbook — and the clock is running.1

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up. Since November 2026 he reviews and approves every article under his name before publication.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com